Contact Us

Defective Drugs
*    Denotes required field.

   * First Name 

   * Last Name 

   * Email 

Phone 

Cell Phone 

Street Address 

Zip Code 

City 

State 

   * Name of drug: 

Date you started taking this drug:

Date you stopped taking this drug:

Please describe side effects:

For verification purposes, please answer the below question:
+
=

No Yes, I agree to the Parker Waichman LLP disclaimers. Click here to review.

Yes, I would like to receive the Parker Waichman LLP monthly newsletter, InjuryAlert.

please do not fill out the field below.


Genentech Issues Warning About Eye Drug Lucentis

Jan 27, 2007 | NewsInferno.com

In a letter sent to 1,500 eye doctors, Genentech is warning that its macular degeneration drug, Lucentis, may increase the risk of stroke if administered in high doses. Approved a mere six months ago by the FDA, Lucentis has already generated nearly $400 million in sales for Genentech, although the latest news may hurt the drug’s economic performance.

The company announced that preliminary findings from a 5,000-patient trial found that 1.2 percent of patients taking high doses (0.5 mg) of Lucentis suffered a stroke while only 0.3 percent of low-dose (0.3 mg) patients had a stroke. The difference in dosages does not appear to affect the incidence of heart failure.

Genentech has alerted the FDA about their latest findings and does not anticipate the agency making any labeling changes or safety warnings. The Lucentis label already has a warning about blood-clot-related risks such as strokes and heart attacks.

For most patients, the price tag for Lucentis is roughly $10,000 per year. Macular degeneration is the leading cause of blindness in elderly patients, and the drug has become wildly popular as a remedy for vision problems among that population.


Other articles
Parker Waichman Accolades And Reviews Best Lawyers Find Us On Avvo